Whalesbook
Many investors wrongly assume that holding a patent allows a company to sell its product freely. In reality, Indian patent law grants the right to exclude others, not a guarantee that you are free to commercialize. This gap creates significant legal and financial risks, particularly in sectors like pharma and technology. For investors, understanding the difference between patentability and the Freedom-to-Operate (FTO) assessment is crucial for evaluating a company's execution risk and long-term financial stability.
What Happened
There is a common misunderstanding among market participants regarding intellectual property rights. Many assume that receiving a patent from the Indian government provides an automatic right to manufacture and sell that product. However, under Section 48 of the Patents Act, 1970, a patent primarily grants the holder an 'exclusionary right.' This means the patent owner can legally stop others from using their invention, but it does not automatically grant the patent holder the right to sell their own product without potentially infringing on someone else’s pre-existing patent.
Why This Matters For Investors
For investors, the distinction between owning a patent and having the right to sell a product is a critical matter of risk management. If a company launches a product without performing a proper 'Freedom-to-Operate' (FTO) assessment, they may inadvertently infringe on a competitor's valid and enforceable patent. This can lead to costly litigation, court injunctions, and the potential forced withdrawal of products from the market. Such events can severely impact a company's revenue, margins, and reputation, turning a promising product launch into a significant liability.
The Gap Between Regulatory Approval and Patent Clearance
One of the most important aspects for investors to understand is the difference between regulatory approval and patent clearance. For example, in the pharmaceutical sector, a company may receive approval from the Central Drugs Standard Control Organisation (CDSCO) to sell a drug. However, this regulatory approval does not mean the product is free from patent issues. India does not operate under a 'patent linkage' system, where the government checks for patent conflicts before granting regulatory clearance. Therefore, it is entirely the company’s responsibility to ensure that launching a drug does not violate any third-party patents. A company can have a fully compliant product from a regulatory perspective but still face a legal shutdown due to patent infringement.
The Risk of Legal Battles
Legal risk is often underestimated until it hits the balance sheet. When a company is accused of patent infringement, the court process can be long and expensive. If an Indian court finds that a company is infringing on 'pith and marrow' of a competitor's invention—even with minor changes—it can halt operations. This introduces a 'execution risk' where business projections, product timelines, and capital spending on manufacturing capacity could go to waste if the product is pulled off shelves.
What Investors Should Track
Investors may want to monitor how companies manage their legal and intellectual property (IP) risks. A well-managed company typically conducts a thorough FTO assessment before investing large sums in a new product launch. Investors can watch for disclosures in annual reports or management commentary regarding pending litigation, potential infringement risks, or licensing agreements. If a company has a history of 'designing around' existing patents—meaning they actively develop unique solutions that avoid infringing on competitors—it may indicate a more mature approach to legal risk. The absence of such due diligence can make a company vulnerable to sudden and unpredictable legal costs.